{"id":"https://openalex.org/W73977860","doi":null,"title":"Novel targeted agents in Her-2 positive and triple negative breast cancer","display_name":"Novel targeted agents in Her-2 positive and triple negative breast cancer","publication_year":2013,"publication_date":"2013-11-01","ids":{"openalex":"https://openalex.org/W73977860","mag":"73977860"},"language":"en","primary_location":{"id":"pmh:http://www.rian.ie/71541/","doi":null,"is_oa":true,"landing_page_url":"http://doras.dcu.ie/18334/","pdf_url":"http://doras.dcu.ie/18334/","source":{"id":"https://openalex.org/S4306400033","display_name":"Arrow@dit (Dublin Institute of Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210144925","host_organization_name":"Technological University Dublin","host_organization_lineage":["https://openalex.org/I4210144925"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Tryfonopoulos, Dimitrios (2013) Novel targeted agents in Her-2 positive and triple negative breast cancer. Master of Science thesis, Dublin City University.","raw_type":"Other"},"volume":null,"type":"other","is_traditional":false,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://doras.dcu.ie/18334/","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029704952","display_name":"Dimitrios J. Tryfonopoulos","orcid":"https://orcid.org/0000-0003-3650-8247","observed_orcids":["https://orcid.org/0000-0003-3650-8247"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Dimitrios Tryfonopoulos","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5029704952"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9761000275611877,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9761000275611877,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.017100000753998756,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9319999814033508},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.972000002861023},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.9229999780654907},{"id":"https://openalex.org/keywords/sunitinib","display_name":"sunitinib","score":0.9049999713897705},{"id":"https://openalex.org/keywords/multikinase-inhibitor","display_name":"multikinase inhibitor","score":0.9269999861717224},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.7129999995231628},{"id":"https://openalex.org/keywords/caveolin-1","display_name":"caveolin-1","score":0.9020000100135803},{"id":"https://openalex.org/keywords/caveolin-2","display_name":"caveolin-2","score":1.0},{"id":"https://openalex.org/keywords/src-family-kinases","display_name":"Src family kinases","score":0.7680000066757202},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.8769999742507935},{"id":"https://openalex.org/keywords/drug-sensitivity","display_name":"drug sensitivity","score":0.824999988079071},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6179999709129333},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.7540000081062317}],"concepts":[{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.9633055925369263},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.7855026721954346},{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.7057406902313232},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6164991855621338},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5758759379386902},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5432279706001282},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.5023677349090576},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4961431920528412},{"id":"https://openalex.org/C108636557","wikidata":"https://www.wikidata.org/wiki/Q21109354","display_name":"Proto-oncogene tyrosine-protein kinase Src","level":3,"score":0.4868254065513611},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.47306644916534424},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4402278959751129},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.436354398727417},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2664901912212372}],"mesh":[],"locations_count":3,"locations":[{"id":"pmh:http://www.rian.ie/71541/","doi":null,"is_oa":true,"landing_page_url":"http://doras.dcu.ie/18334/","pdf_url":"http://doras.dcu.ie/18334/","source":{"id":"https://openalex.org/S4306400033","display_name":"Arrow@dit (Dublin Institute of Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210144925","host_organization_name":"Technological University Dublin","host_organization_lineage":["https://openalex.org/I4210144925"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Tryfonopoulos, Dimitrios (2013) Novel targeted agents in Her-2 positive and triple negative breast cancer. Master of Science thesis, Dublin City University.","raw_type":"Other"},{"id":"pmh:oai:doras.dcu.ie:18334","doi":null,"is_oa":true,"landing_page_url":"https://doras.dcu.ie/18334/1/Dimitrios_Tryfonopoulos_MSc.pdf","pdf_url":"http://doras.dcu.ie/18334/1/Dimitrios_Tryfonopoulos_MSc.pdf","source":{"id":"https://openalex.org/S4306401511","display_name":"Dublin City University Open Access Institutional Repository (Dublin City University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I42934936","host_organization_name":"Dublin City University","host_organization_lineage":["https://openalex.org/I42934936"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Thesis"},{"id":"mag:73977860","doi":null,"is_oa":false,"landing_page_url":"http://doras.dcu.ie/18334/1/Dimitrios_Tryfonopoulos_MSc.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"pmh:http://www.rian.ie/71541/","doi":null,"is_oa":true,"landing_page_url":"http://doras.dcu.ie/18334/","pdf_url":"http://doras.dcu.ie/18334/","source":{"id":"https://openalex.org/S4306400033","display_name":"Arrow@dit (Dublin Institute of Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210144925","host_organization_name":"Technological University Dublin","host_organization_lineage":["https://openalex.org/I4210144925"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Tryfonopoulos, Dimitrios (2013) Novel targeted agents in Her-2 positive and triple negative breast cancer. Master of Science thesis, Dublin City University.","raw_type":"Other"},"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G2516316913","display_name":null,"funder_award_id":"CSA/2007/11","funder_id":"https://openalex.org/F4320312041","funder_display_name":"Health Research Board"}],"funders":[{"id":"https://openalex.org/F4320312041","display_name":"Health Research Board","ror":"https://ror.org/003hb2249"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W73977860.pdf","grobid_xml":"https://content.openalex.org/works/W73977860.grobid-xml"},"referenced_works_count":107,"referenced_works":["https://openalex.org/W51995314","https://openalex.org/W171927321","https://openalex.org/W196543165","https://openalex.org/W1224381932","https://openalex.org/W1523531555","https://openalex.org/W1529396499","https://openalex.org/W1533898383","https://openalex.org/W1564577788","https://openalex.org/W1594899067","https://openalex.org/W1644299043","https://openalex.org/W1863396779","https://openalex.org/W1899552864","https://openalex.org/W1967720639","https://openalex.org/W1969345980","https://openalex.org/W1972035895","https://openalex.org/W1973268287","https://openalex.org/W1973555911","https://openalex.org/W1974024530","https://openalex.org/W1976858755","https://openalex.org/W1977455794","https://openalex.org/W1978219486","https://openalex.org/W1983268106","https://openalex.org/W1988610380","https://openalex.org/W1990801049","https://openalex.org/W2002121555","https://openalex.org/W2002814533","https://openalex.org/W2012247982","https://openalex.org/W2015511456","https://openalex.org/W2016905164","https://openalex.org/W2021357757","https://openalex.org/W2021597940","https://openalex.org/W2032225894","https://openalex.org/W2035387891","https://openalex.org/W2036988959","https://openalex.org/W2043343551","https://openalex.org/W2043824170","https://openalex.org/W2044858733","https://openalex.org/W2049547244","https://openalex.org/W2050596106","https://openalex.org/W2052370726","https://openalex.org/W2053223343","https://openalex.org/W2066003961","https://openalex.org/W2077945404","https://openalex.org/W2082004605","https://openalex.org/W2086262311","https://openalex.org/W2087186976","https://openalex.org/W2092343827","https://openalex.org/W2092661658","https://openalex.org/W2094114923","https://openalex.org/W2096502221","https://openalex.org/W2097255042","https://openalex.org/W2097946794","https://openalex.org/W2098073308","https://openalex.org/W2099335989","https://openalex.org/W2101257013","https://openalex.org/W2106292881","https://openalex.org/W2109439031","https://openalex.org/W2109462974","https://openalex.org/W2110514539","https://openalex.org/W2111429259","https://openalex.org/W2113633750","https://openalex.org/W2115759102","https://openalex.org/W2118605519","https://openalex.org/W2126275851","https://openalex.org/W2126575569","https://openalex.org/W2127057139","https://openalex.org/W2128230789","https://openalex.org/W2132537022","https://openalex.org/W2134133462","https://openalex.org/W2135244179","https://openalex.org/W2136929338","https://openalex.org/W2138067522","https://openalex.org/W2138095640","https://openalex.org/W2140684853","https://openalex.org/W2141393790","https://openalex.org/W2141719586","https://openalex.org/W2142786915","https://openalex.org/W2143974518","https://openalex.org/W2148024451","https://openalex.org/W2149257337","https://openalex.org/W2151837479","https://openalex.org/W2152654745","https://openalex.org/W2153454576","https://openalex.org/W2153457729","https://openalex.org/W2154142993","https://openalex.org/W2156447034","https://openalex.org/W2157840751","https://openalex.org/W2158927987","https://openalex.org/W2159459001","https://openalex.org/W2159967578","https://openalex.org/W2161770015","https://openalex.org/W2161792005","https://openalex.org/W2163606994","https://openalex.org/W2165662097","https://openalex.org/W2166199281","https://openalex.org/W2167188058","https://openalex.org/W2188965426","https://openalex.org/W2204424558","https://openalex.org/W2213952892","https://openalex.org/W2318605753","https://openalex.org/W2319396156","https://openalex.org/W2328452031","https://openalex.org/W2337704846","https://openalex.org/W2410770797","https://openalex.org/W2497192675","https://openalex.org/W2589359420","https://openalex.org/W2900933517"],"related_works":["https://openalex.org/W2249514429","https://openalex.org/W2151837479","https://openalex.org/W2330722755","https://openalex.org/W2604956722","https://openalex.org/W2043824170","https://openalex.org/W2240617428","https://openalex.org/W2145430926","https://openalex.org/W2885655838","https://openalex.org/W3003174025","https://openalex.org/W2936978491"],"abstract_inverted_index":{"The":[0],"development":[1],"of":[2,66,93,131,140,181,202,215,229,287],"Her-2":[3,13,20,27,37,47,76,95,122,143],"targeted":[4,38,55],"therapies":[5],"has":[6],"improved":[7,112],"the":[8,94,120,132,141,152,163,227,238],"prognosis":[9],"for":[10,58,276,291],"patients":[11],"with":[12,26,89,107,187,210,223,233,246,256,270],"positive":[14,21,77,96,123,144],"breast":[15,49,61,81,175,280],"cancer.":[16],"However,":[17],"not":[18],"all":[19],"tumours":[22],"respond":[23],"to":[24,34,102,115,151,170,179,197],"treatment":[25,106],"antagonists.":[28],"Triple":[29],"negative":[30,60,80,135,174,261],"cancers":[31],"are":[32],"resistant":[33],"hormone":[35],"and":[36,51,73,78,86,109,162,218,282,296],"therapies.":[39],"This":[40],"project":[41],"focused":[42],"on":[43,52,149],"improving":[44],"response":[45,113,150],"in":[46,75,87,119,129,137,172,226,237,244,258,278],"overexpressing":[48],"cancer":[50,82,176],"developing":[53],"effective":[54],"therapy":[56],"strategies":[57],"triple":[59,79,134,173,260],"cancer.\\nWe":[62],"tested":[63],"a":[64,273,285],"number":[65],"multi-target":[67,154],"kinase":[68,155],"inhibitors":[69],"(imatinib,":[70],"sunitinib,":[71],"pazopanib":[72],"dasatinib)":[74],"cell":[83,97,124,145,230,241,262],"lines,":[84],"alone":[85],"combination":[88,245,275],"other":[90,153],"agents.":[91],"\\nTwo":[92],"lines":[98,125,146],"showed":[99,111],"moderate":[100],"sensitivity":[101,169,196,225,293],"sunitinib":[103,108],"malate.":[104],"Combined":[105],"trastuzumab":[110],"compared":[114],"either":[116],"drug":[117],"alone,":[118],"four":[121],"tested.\\nDasatinib":[126],"inhibited":[127],"growth":[128],"3":[130],"5":[133],"but":[136,199],"only":[138],"1":[139,217],"4":[142],"tested.":[147],"Based":[148],"inhibitors,":[156],"which":[157],"have":[158,267,283],"overlapping":[159],"target":[160],"specificities,":[161],"Src,PP2,":[164],"our":[165],"results":[166],"suggest":[167],"that":[168],"dasatinib":[171,211,224,269,292],"is":[177],"due":[178],"inhibition":[180],"ephrin":[182],"type":[183,204],"A":[184,205],"receptors.":[185],"Consistent":[186],"this":[188],"hypothesis,":[189],"neither":[190],"Src":[191],"expression":[192],"nor":[193],"phosphorylation":[194],"predicted":[195],"dasatinib,":[198],"high":[200],"levels":[201,214],"Ephrin":[203],"receptor":[206],"2":[207,220],"protein":[208],"correlated":[209,222],"sensitivity.":[212],"High":[213],"caveolin":[216,219],"also":[221],"panel":[228,286],"lines.\\nDasatinib":[231],"combined":[232],"cisplatin":[234,271],"was":[235,254],"synergistic":[236],"three":[239],"dasatinib-sensitive":[240],"lines.":[242,263],"Dasatinib,":[243],"5\u2019-deoxy-5\u2019-fluoruridine,":[247],"displayed":[248],"synergy":[249,253],"or":[250],"additivity.":[251],"Moderate":[252],"observed":[255],"docetaxel":[257],"two":[259],"\\nIn":[264],"conclusion,":[265],"we":[266],"identified":[268,284],"as":[272],"rational":[274],"testing":[277],"triple-negative":[279],"cancer,":[281],"putative":[288],"predictive":[289],"biomarkers":[290],"(EphA2,":[294],"CAV1":[295],"CAV2).":[297]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2016-06-24T00:00:00"}